[go: up one dir, main page]

CO2017004382A2 - Composiciones farmacéuticas que comprenden lobeglitazona para administración oral - Google Patents

Composiciones farmacéuticas que comprenden lobeglitazona para administración oral

Info

Publication number
CO2017004382A2
CO2017004382A2 CONC2017/0004382A CO2017004382A CO2017004382A2 CO 2017004382 A2 CO2017004382 A2 CO 2017004382A2 CO 2017004382 A CO2017004382 A CO 2017004382A CO 2017004382 A2 CO2017004382 A2 CO 2017004382A2
Authority
CO
Colombia
Prior art keywords
pharmaceutical compositions
lobeglitazone
oral administration
present
cellulose derivatives
Prior art date
Application number
CONC2017/0004382A
Other languages
English (en)
Inventor
Dae Young Jung
Taek Hwan Shin
Min Jae Joo
Shin Jung Park
Jong Lae Lim
Original Assignee
Chong Kun Dang Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chong Kun Dang Pharmaceutical Corp filed Critical Chong Kun Dang Pharmaceutical Corp
Publication of CO2017004382A2 publication Critical patent/CO2017004382A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas para administración oral que comprenden lobeglitazona. Las composiciones farmacéuticas de la presente invención tienen excelente velocidad de disolucion y expresan rápidos efectos farmacológicos al comprender derivados de celulosa.
CONC2017/0004382A 2014-11-06 2017-05-02 Composiciones farmacéuticas que comprenden lobeglitazona para administración oral CO2017004382A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020140153759A KR101721831B1 (ko) 2014-11-06 2014-11-06 로베글리타존을 함유하는 경구 투여용 약제학적 조성물
PCT/KR2015/011801 WO2016072748A1 (en) 2014-11-06 2015-11-04 Pharmaceutical compositions comprising lobeglitazone for oral administration

Publications (1)

Publication Number Publication Date
CO2017004382A2 true CO2017004382A2 (es) 2017-07-19

Family

ID=55909398

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0004382A CO2017004382A2 (es) 2014-11-06 2017-05-02 Composiciones farmacéuticas que comprenden lobeglitazona para administración oral

Country Status (7)

Country Link
KR (1) KR101721831B1 (es)
CN (1) CN107072954B (es)
CL (1) CL2017001077A1 (es)
CO (1) CO2017004382A2 (es)
PE (1) PE20170909A1 (es)
RU (1) RU2709526C2 (es)
WO (1) WO2016072748A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230165301A (ko) * 2021-04-01 2023-12-05 아클립스 투 인크. 신장 질환의 치료
KR102739882B1 (ko) * 2021-04-02 2024-12-06 연세대학교 원주산학협력단 로베글리타존을 유효성분으로 하는 안과질환 치료용 조성물
KR20250005317A (ko) * 2022-04-20 2025-01-09 아클립스 투 인크. 위장 질환의 치료

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977158A (en) * 1996-11-28 1999-11-02 Novo Nordisk A/S Pharmaceutical formulations comprising levormeloxifene compounds
CA2476587C (en) * 2002-02-26 2010-05-04 Astrazeneca Ab Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
KR100450700B1 (ko) 2002-03-22 2004-10-01 주식회사종근당 티아졸리딘디온 유도체 화합물 및 이를 함유하는 약제학적조성물
RU2442585C2 (ru) * 2007-05-31 2012-02-20 Си Ви Терапьютикс, Инк. Способ лечения диабета
US8785608B2 (en) * 2009-08-26 2014-07-22 Sanofi Crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
RU2012131509A (ru) * 2009-12-24 2014-01-27 Эбботт Хелткеа Прайвит Лимитед Быстрорастворимая фармацевтическая композиция, содержащая лорноксикам
CN102274162A (zh) * 2011-08-02 2011-12-14 无锡万全医药技术有限公司 一种含有难溶性药物和亲水凝胶材料的固体组合物及其制备方法
EP2755651A1 (en) * 2011-09-13 2014-07-23 Biomed Valley Discoveries, Inc. Compositions and methods for treating metabolic disorders

Also Published As

Publication number Publication date
CN107072954A (zh) 2017-08-18
KR101721831B1 (ko) 2017-03-31
RU2017119465A (ru) 2018-12-06
CN107072954B (zh) 2023-05-26
CL2017001077A1 (es) 2018-03-16
PE20170909A1 (es) 2017-07-12
RU2709526C2 (ru) 2019-12-18
RU2017119465A3 (es) 2019-05-28
KR20160054317A (ko) 2016-05-16
WO2016072748A1 (en) 2016-05-12

Similar Documents

Publication Publication Date Title
CY1123953T1 (el) Καθυστερημενης απελευθερωσης συνθεσεις λινακλοτιδης
CO2017012786A2 (es) Nuevos derivados hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen
DK3236943T3 (da) Sammensætninger til ileo-jejunal lægemiddeladministration
EP3256138A4 (en) PHARMACEUTICAL COMPOSITIONS WITH MELOXICAM
HUE042449T2 (hu) Új 4-metoxi-pirrolszármazékok vagy sóik és az azokat tartalmazó gyógyászati készítmények
EA201691582A1 (ru) Новые фармацевтические препараты
HUE054389T2 (hu) Eljárás CFTR-mediálta betegségek kezelésére szolgáló gyógyászati kompozíciók elõállítására
DOP2018000059A (es) Composiciones de insulina de rápida acción
PT3357491T (pt) Composição farmacêutica para distribuir um fármaco aniónico
EP3641771A4 (en) PHARMACEUTICAL COMPOSITIONS
MX2015012833A (es) Composiciones antibioticas de ceftolozano.
EP3616696A4 (en) PHARMACEUTICAL COMPOSITION CONTAINING ENZALUTAMIDE WHICH MAY BE ADMINISTERED ORALLY
MX2016011290A (es) Composiciones de ester de colina de acido lipoico y metodos de uso.
UY35997A (es) Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CL2017000587A1 (es) Derivados de tetrahidroquinolina como inhibidores de bromodominio
GT201600252A (es) Derivados de naftiridinadiona
EP3344293A4 (en) VLP-STABILIZED VACCINE COMPOSITIONS
DK3313370T3 (da) Oftalmologisk farmaceutisk sammensætning
EP3244930A4 (en) PHARMACEUTICAL COMPOSITIONS WITH POH DERIVATIVES
SI3318259T1 (sl) Stabilni farmacevtski sestavki za oralno dajanje
CO2017004382A2 (es) Composiciones farmacéuticas que comprenden lobeglitazona para administración oral
BR112016028083A2 (pt) Composição oral farmacêutica de isotretinoina e seu processo de preparação
MX376741B (es) Composición farmaceútica de sulfonamida
HUE057871T2 (hu) Gyógyászati hatóanyagokat tartalmazó hialuronán konjugátumok, eljárások és kompozíciók
EA201400444A1 (ru) Производные 2-оксопиперидинила